Peapod Lane Capital LLC purchased a new stake in shares of Climb Bio, Inc. (NASDAQ:CLYM - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 553,816 shares of the company's stock, valued at approximately $676,000. Peapod Lane Capital LLC owned approximately 0.82% of Climb Bio at the end of the most recent reporting period.
Separately, Bank of New York Mellon Corp purchased a new position in shares of Climb Bio in the first quarter worth $79,000. Institutional investors and hedge funds own 69.76% of the company's stock.
Wall Street Analysts Forecast Growth
CLYM has been the topic of several research analyst reports. BTIG Research initiated coverage on shares of Climb Bio in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. Oppenheimer initiated coverage on shares of Climb Bio in a report on Friday, June 6th. They issued an "outperform" rating and a $10.00 target price on the stock.
Check Out Our Latest Stock Analysis on CLYM
Climb Bio Price Performance
Shares of CLYM stock remained flat at $1.35 during mid-day trading on Thursday. 137,351 shares of the stock traded hands, compared to its average volume of 294,059. Climb Bio, Inc. has a 1 year low of $1.05 and a 1 year high of $9.21. The company has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.45. The stock has a market capitalization of $91.23 million, a P/E ratio of -0.57 and a beta of -0.13.
Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16). As a group, equities analysts expect that Climb Bio, Inc. will post -1.57 earnings per share for the current year.
Climb Bio Company Profile
(
Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
